Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Stopped early · Phase 1/Phase 2
Conditions studied: Non-Hodgkin Lymphoma
In brief
The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.
Key facts
- Study ID
- NCT02568683
- Run by
- Gilead Sciences
- People needed
- 10
- Starts
- 2016-02-11
- Expected to finish
- 2017-06-22
- Last updated by the study team
- 2019-04-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Forrest General Hospital — Hattiesburg, Mississippi, United States
- Medical University of South Carolina — Charleston, South Carolina, United States
- Groupe Hospitalier du Haut Leveque — Pessac, Aquitaine, France
- Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille) — Lille, Hauts-de-France, France
- Institut Paoli Calmettes — Marseille, Provence-Alpes-Côte d'Azur Region, France
- Centre Hospitalier Universitaire de Dijon Hôpital du Bocage — Dijon, France
- Centre Hospital Lyon Sud — Pierre-Bénite, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.